Description

Epkinly (epcoritamab-bysp)

Epkinly is a prescription cancer medicine that contains the active ingredient epcoritamab-bysp. It is a type of immunotherapy known as a bispecific CD20-directed CD3 T-cell engager, designed to help the body’s immune system recognize and destroy certain cancerous B cells. Epkinly is administered as a subcutaneous injection (an injection under the skin) by a healthcare professional.

Uses

Epkinly is approved for the treatment of adults with certain types of B-cell lymphomas, including:

• Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more prior systemic treatments.
• Relapsed or refractory follicular lymphoma (FL) after previous treatments.
• In some cases, follicular lymphoma may be treated with Epkinly in combination with other medicines such as lenalidomide and rituximab.

How It Works

Epkinly works by binding to two targets at the same time:

• CD20 on cancerous B cells.
• CD3 on T cells (immune cells).

This action brings T cells into contact with the cancer cells, enabling the immune system to attack and destroy the lymphoma cells.

Administration

Treatment follows a step-up dosing schedule, where patients receive smaller initial doses before receiving the full dose. This approach helps reduce the risk of serious immune-related side effects. The medication is given in treatment cycles under medical supervision.

Common Side Effects

Common side effects may include:

• Cytokine Release Syndrome (CRS)
• Injection-site reactions
• Fatigue
• Fever
• Diarrhea
• Rash
• Muscle and joint pain
• Abdominal pain
• Respiratory infections and COVID-19 infections reported during studies

Important Safety Warnings

Epkinly carries boxed warnings for:

• Cytokine Release Syndrome (CRS), a potentially serious immune reaction.
• Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), which can affect the nervous system.

Patients receiving Epkinly require close monitoring, especially during the initial treatment cycles.

Conclusion

Epkinly is an advanced immunotherapy used to treat certain relapsed or refractory B-cell lymphomas. By engaging the body’s immune system to attack cancer cells, it offers a treatment option for patients whose disease has returned or has not responded to previous therapies. Treatment should always be managed by qualified oncology specialists due to the risk of serious side effects and the need for careful monitoring.